Bunz F
Radiation Biology Program, The Johns Hopkins Oncology Center, The Johns Hopkins School of Medicine, Baltimore, MD 21231, USA.
Curr Opin Pharmacol. 2001 Aug;1(4):337-41. doi: 10.1016/s1471-4892(01)00059-5.
Successful cancer therapy requires the selective killing of cancer cells. Many molecular components of the pathways that lead to cell death have recently been identified and a number of these, including p53, Apaf-1, and members of the inhibitor of apoptosis protein and Bcl-2 gene families, have been found to be altered or disregulated in many cancers. These recent advances and the ongoing elucidation of how these pathways work is providing clues as to how therapeutically resistant cancers might be attacked.
成功的癌症治疗需要选择性地杀死癌细胞。最近已经确定了导致细胞死亡的许多信号通路中的分子成分,并且发现其中一些成分,包括p53、凋亡蛋白酶激活因子1(Apaf-1)以及凋亡抑制蛋白和Bcl-2基因家族的成员,在许多癌症中发生了改变或失调。这些最新进展以及对这些信号通路如何运作的不断阐明,为攻克具有治疗抗性的癌症提供了线索。